Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer

IF 2.9 2区医学 Q2 ONCOLOGY

Cancer Medicine Pub Date : 2023-09-29 DOI:10.1002/cam4.6575

Zhening Zhang, Yiyi Yu, Tong Xie, Changsong Qi, Xiaotian Zhang, Lin Shen, Zhi Peng

{"title":"Pulmonary lymphangitis carcinomatosis: A peculiar presentation clustering in MET-amplified gastric cancer","authors":"Zhening Zhang, Yiyi Yu, Tong Xie, Changsong Qi, Xiaotian Zhang, Lin Shen, Zhi Peng","doi":"10.1002/cam4.6575","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>The clinicopathological features of MET-amplified gastric cancer (GC) and real-world data on the efficacy of MET-targeted therapies remain unknown. Pulmonary lymphangitis carcinomatosis (PLC) is a peculiar manifestation of GC, whose management has not been thoroughly described.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This study analyzed patients diagnosed with MET-amplified GC or GC with PLC at any time point of the disease course from 2011 to 2021 in two centers. Clinicopathological features and survival outcomes of MET-amplified GC were analyzed. The clinical and molecular implications of GC with PLC were discussed.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>Fifty-eight patients with MET-amplified GC and 20 patients with GC accompanied by PLC were finally enrolled for analysis (including 13 overlapped patients). GC with PLC was more common in female patients (<i>p</i> = 0.010), diagnosed at a younger age (<i>p</i> = 0.002), presented with a higher baseline ECOG PS (<i>p</i> = 0.016), and was more likely to develop lung metastasis (<i>p</i> < 0.001), and serous effusion (<i>p</i> = 0.026) than GC without PLC. Patients with primary MET-amplified GC had a worse prognosis than those with secondary MET-amplified GC (<i>p</i> = 0.005). The application of anti-MET therapy was associated with numerically prolonged survival, but the association was not statistically significant (<i>p</i> = 0.07). MET amplification was concentrated in patients with PLC, in which anti-MET therapies elicited a high response rate.</p>\n </section>\n \n <section>\n \n <h3> Conclusions</h3>\n \n <p>MET-targeted therapies are efficacious in real-world populations with MET-amplified GC. Patients with PLC have distinct clinical and molecular features and might benefit from MET-targeted therapies.</p>\n </section>\n </div>","PeriodicalId":139,"journal":{"name":"Cancer Medicine","volume":"12 19","pages":"19583-19594"},"PeriodicalIF":2.9000,"publicationDate":"2023-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1002/cam4.6575","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Cancer Medicine","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1002/cam4.6575","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ONCOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

The clinicopathological features of MET-amplified gastric cancer (GC) and real-world data on the efficacy of MET-targeted therapies remain unknown. Pulmonary lymphangitis carcinomatosis (PLC) is a peculiar manifestation of GC, whose management has not been thoroughly described.

Methods

This study analyzed patients diagnosed with MET-amplified GC or GC with PLC at any time point of the disease course from 2011 to 2021 in two centers. Clinicopathological features and survival outcomes of MET-amplified GC were analyzed. The clinical and molecular implications of GC with PLC were discussed.

Results

Fifty-eight patients with MET-amplified GC and 20 patients with GC accompanied by PLC were finally enrolled for analysis (including 13 overlapped patients). GC with PLC was more common in female patients (p = 0.010), diagnosed at a younger age (p = 0.002), presented with a higher baseline ECOG PS (p = 0.016), and was more likely to develop lung metastasis (p < 0.001), and serous effusion (p = 0.026) than GC without PLC. Patients with primary MET-amplified GC had a worse prognosis than those with secondary MET-amplified GC (p = 0.005). The application of anti-MET therapy was associated with numerically prolonged survival, but the association was not statistically significant (p = 0.07). MET amplification was concentrated in patients with PLC, in which anti-MET therapies elicited a high response rate.

Conclusions

MET-targeted therapies are efficacious in real-world populations with MET-amplified GC. Patients with PLC have distinct clinical and molecular features and might benefit from MET-targeted therapies.

Abstract Image

查看原文本刊更多论文

肺淋巴管炎癌性病变：MET型癌症的一种特殊表现。

背景：MET-放大型癌症（GC）的临床病理特征和MET-靶向治疗疗效的真实数据尚不清楚。肺淋巴管炎-癌性病变（PLC）是GC的一种特殊表现，其治疗尚未得到彻底的描述。方法：本研究分析了2011年至2021年两个中心在病程的任何时间点诊断为MET扩增GC或GC伴PLC的患者。分析MET扩增GC的临床病理特征和生存结果。讨论了GC与PLC的临床和分子意义。结果：58例MET扩增GC患者和20例GC伴PLC患者（包括13例重叠患者）最终被纳入分析。GC合并PLC在女性患者中更常见（p = 0.010），诊断年龄较小（p = 0.002），表现为较高的基线ECOG PS（p = 0.016），更容易发生肺转移（p 结论：MET靶向治疗在MET扩增GC的真实人群中是有效的。PLC患者具有不同的临床和分子特征，可能受益于MET靶向治疗。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer Medicine ONCOLOGY-

CiteScore

5.50

自引率

2.50%

发文量

907

审稿时长

19 weeks

期刊介绍： Cancer Medicine is a peer-reviewed, open access, interdisciplinary journal providing rapid publication of research from global biomedical researchers across the cancer sciences. The journal will consider submissions from all oncologic specialties, including, but not limited to, the following areas: Clinical Cancer Research Translational research ∙ clinical trials ∙ chemotherapy ∙ radiation therapy ∙ surgical therapy ∙ clinical observations ∙ clinical guidelines ∙ genetic consultation ∙ ethical considerations Cancer Biology: Molecular biology ∙ cellular biology ∙ molecular genetics ∙ genomics ∙ immunology ∙ epigenetics ∙ metabolic studies ∙ proteomics ∙ cytopathology ∙ carcinogenesis ∙ drug discovery and delivery. Cancer Prevention: Behavioral science ∙ psychosocial studies ∙ screening ∙ nutrition ∙ epidemiology and prevention ∙ community outreach. Bioinformatics: Gene expressions profiles ∙ gene regulation networks ∙ genome bioinformatics ∙ pathwayanalysis ∙ prognostic biomarkers. Cancer Medicine publishes original research articles, systematic reviews, meta-analyses, and research methods papers, along with invited editorials and commentaries. Original research papers must report well-conducted research with conclusions supported by the data presented in the paper.